Another Rush to Judgement: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...
Saved in:
Main Author: | Paul Langley (Author) |
---|---|
Format: | Book |
Published: |
University of Minnesota Libraries Publishing,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017) -
Transparency, Imaginary Worlds and ICER Value Assessments
by: Paul C. Langley
Published: (2017) -
ICER, ISPOR AND QALYs: A Tale of Imaginary Worlds
by: Paul Langley
Published: (2019) -
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
by: Paul Langley
Published: (2018) -
Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds
by: Paul Langley
Published: (2018)